Odyssey Therapeutics (NASDAQ:ODTX) Earns Outperform Rating from Analysts at Wedbush

Research analysts at Wedbush began coverage on shares of Odyssey Therapeutics (NASDAQ:ODTX) in a note issued to investors on Tuesday, Marketbeat Ratings reports. The brokerage set an “outperform” rating and a $30.00 price target on the stock. Wedbush’s target price indicates a potential upside of 76.89% from the company’s previous close.

Other equities analysts have also recently issued reports about the stock. Cantor Fitzgerald initiated coverage on shares of Odyssey Therapeutics in a research report on Tuesday. They issued an “overweight” rating for the company. TD Cowen initiated coverage on shares of Odyssey Therapeutics in a research report on Tuesday. They issued a “buy” rating for the company. Oppenheimer initiated coverage on shares of Odyssey Therapeutics in a research report on Tuesday. They issued an “outperform” rating and a $40.00 price target for the company. Finally, Wall Street Zen upgraded shares of Odyssey Therapeutics to a “hold” rating in a research report on Saturday, May 16th. Five investment analysts have rated the stock with a Buy rating, According to MarketBeat.com, the stock presently has a consensus rating of “Buy” and a consensus price target of $32.00.

Odyssey Therapeutics Trading Down 0.3%

Shares of NASDAQ ODTX opened at $16.96 on Tuesday. Odyssey Therapeutics has a 52-week low of $15.35 and a 52-week high of $20.30.

Insider Activity at Odyssey Therapeutics

In other news, Director Shelley Chu acquired 11,111 shares of the firm’s stock in a transaction dated Monday, May 11th. The stock was bought at an average cost of $18.00 per share, for a total transaction of $199,998.00. Following the completion of the transaction, the director directly owned 11,111 shares in the company, valued at $199,998. This represents a ∞ increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, major shareholder Sr One Capital Management, Llc sold 1,780 shares of the firm’s stock in a transaction on Monday, May 11th. The stock was sold at an average price of $18.00, for a total transaction of $32,040.00. Following the completion of the sale, the insider owned 440,981 shares of the company’s stock, valued at $7,937,658. The trade was a 0.40% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders acquired a total of 4,183,777 shares of company stock valued at $75,319,986 over the last 90 days.